MEI Pharma Inc
For the period ended Jun 30, 2024. Filed Sep 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 19, 2024
LITS$0.96+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands)
| CommonShares | AdditionalPaid-InCapital | AccumulatedDeficit | TotalStockholders’Equity | |
|---|---|---|---|---|
| Balance at June 30, 2022 | 6,658 | $426,572 | $(374,159) | $52,413 |
| Net loss | — | — | (31,838) | (31,838) |
| Issuance of common stock for vested restricted stock units | 5 | (40) | — | (40) |
| Issuance of warrants | — | 500 | — | 500 |
| Share-based compensation expense | — | 3,589 | — | 3,589 |
| Balance at June 30, 2023 | 6,663 | 430,621 | (405,997) | 24,624 |
| Net income | — | — | 17,778 | 17,778 |
| Cash dividends declared ($1.75 per share) | — | (11,660) | — | (11,660) |
| Share-based compensation expense | — | 2,278 | — | 2,278 |
| Balance at June 30, 2024 | 6,663 | $421,239 | $(388,219) | $33,020 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.